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Human noroviruses cause more than 90% of epidemic nonbacterial gastroenteritis. However, the role of B
cells and antibody in the immune response to noroviruses is unclear. Previous studies have demonstrated that
human norovirus specific antibody levels increase upon infection, but they may not be protective against
infection. In this report, we used murine norovirus (MNV), an enteric norovirus, as a model to determine the
importance of norovirus specific B cells and immune antibody in clearance of norovirus infection. We show
here that mice genetically deficient in B cells failed to clear primary MNV infection as effectively as wild-type
mice. In addition, adoptively transferred immune splenocytes derived from B-cell-deficient mice or antibody
production-deficient mice were unable to efficiently clear persistent MNV infection in RAG1/ mice. Further,
adoptive transfer of either polyclonal anti-MNV serum or neutralizing anti-MNV monoclonal antibodies was
sufficient to reduce the level of MNV infection both systemically and in the intestine. Together, these data
demonstrate that antibody plays an important role in the clearance of MNV and that immunoglobulin G
anti-norovirus antibody can play an important role in clearing mucosal infection.
Extensive studies have demonstrated that humoral immune
responses are generated by challenge with various norovirus
strains in humans, pigs, cattle, and mice (5, 10, 13, 22, 23, 27,
37, 39, 44–46). Studies of natural norovirus infections in human
populations show that the lowest rates of seroconversion are in
the 0- to 5-year-old age group and, by adulthood, seroconver-
sion rates range from 80 to 100% in most countries (reviewed
in reference 32). Among children 5 years old, a higher base-
line titer of norovirus antibody appears to correlate with pro-
tection from infection; however, in adults, a preexisting titer
does not appear to be protective (37). This suggests that in
children, antibody may be protective, whereas in adults, sero-
positivity may merely be a sign of previous infection. However,
a Norwalk virus challenge study that examined the timing of
virus-specific immunoglobulin A (IgA) production demon-
strated that an elevation in salivary IgA occurred more than 5
days after infection in susceptible individuals, whereas in indi-
viduals resistant to infection, IgA levels were elevated earlier,
1 to 5 days postchallenge (28). This suggests a correlation
between the timing of an increase in norovirus specific mucosal
IgA production and whether virus established a productive
infection in the host.
In humans, several studies have focused on antibody pro-
duction in response to inoculation with norovirus viruslike
particles (VLPs) assembled in the absence of viral replication
by expression of viral capsid proteins (1, 2, 15, 41, 44–47).
These VLPs share epitopes with virions but do not carry viral
genome (14, 21). High doses of VLPs administered intranasally
or perorally (p.o.), with or without adjuvants such as cholera
toxin or Escherichia coli labile toxin, induced mucosal IgA and
serum IgG in human volunteers, calves, pigs, and mice (1, 2, 15,
16, 19, 41, 44–47). The antibody responses that are elicited
following infection with noroviruses are cross-reactive between
strains within the same genogroup, but much less cross-reac-
tive between strains from different genogroups (20, 21, 27).
Importantly, antisera from infected human volunteers and ex-
perimentally vaccinated mice are able to block binding of Nor-
walk and Lordsdale VLPs to ABH histo-blood group antigens
(16, 19, 29). The presence of antibodies that block norovirus
receptor binding suggests that such antibodies could exert a
protective effect against infection or promote resolution of
symptoms. In addition, inoculating mice with vaccine cocktails
comprised of multiple norovirus VLPs enhances the produc-
tion of blocking antibodies, as well as heterotypic antibodies
against strains not included in the cocktail (29). However, no
formal assessment of the physiologic importance of either in-
duced polyclonal or specific antibody isotypes has been under-
taken to date.
Murine norovirus (MNV) is an enteric virus that, like its
human counterparts, is spread by the fecal-oral route (58).
MNV-infected mice make a significant antibody response (17,
18, 23, 40, 53), which can be neutralizing (48). The availability
of a culture system and plaque assay has allowed the isolation
of neutralizing monoclonal antibodies (MAbs) (57). One such
MAb, A6.2, recognizes a structurally constrained epitope that
is present in the surface exposed hypervariable P2 domain of
VP1, the major capsid protein (24, 30, 57). These data suggest
that the antibody response may be important for the control of
MNV infection, but this has not been shown. The question of
whether systemic IgG can play a role in control of mucosal
infection remains controversial.
Here, we report on the role of B cells, polyclonal immune
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antibody, and neutralizing IgG MAbs in the clearance of MNV
infection. Mice that are genetically deficient in B cells (MT
mice) failed to clear primary MNV infection as effectively as
did wild-type mice. Adoptively transferred immune spleno-
cytes from mice either lacking B cells (MT mice) or mice
lacking B cells capable of making virus-specific antibody
(HELMET mice) were unable to clear MNV infection from
the intestine of persistently infected RAG1/ mice. Further,
adoptive transfer of polyclonal anti-MNV serum and IgG anti-
MNV MAbs were sufficient to reduce the level of MNV infec-
tion both systemically and in the intestine. Together, these data
demonstrate that antibody, including IgG, plays an important
role in the clearance of MNV.
MATERIALS AND METHODS
Virus, viral stocks, and plaque assays. MNV strain MNV1.CW3 was used in
all virus infections (57). To generate a concentrated virus stock, RAW 264.7 cells
were infected in VP-SFM media (Gibco, Carlsbad, CA) for 2 days at a multi-
plicity of infection of 0.05. Supernatants were clarified by low-speed centrifuga-
tion for 20 min at 3,000 rpm. Virus was concentrated by centrifugation at 4°C for
3 h at 27,000 rpm (90,000 g) in an SW32 rotor. Viral pellets were resuspended in
phosphate-buffered saline, and titers were determined on RAW 264.7 cells as
previously described (57). Plaque assays were performed as previously described
(57) with the following modifications. Tissues were harvested into sterile, screw-
top 2-ml tubes containing 500 l of 1-mm zirconia/silica beads (BioSpec Prod-
ucts, Bartlesville, OK) and stored at 80°C. To obtain virus titers in these tissues,
1 ml of complete Dulbecco modified Eagle medium was added to each sample on
ice, followed by homogenization using a MagNA Lyser (Roche Applied Science,
Indianapolis, IN) prior to plaque assay. The limit of detection was 20 PFU/ml.
Cell culture and antibodies. RAW 264.7 cells (ATCC, Manassas, VA) were
maintained as described previously (57). MAb 9BG5, specific to the reovirus type
3 hemagglutinin (4, 7), and anti-MNV MAbs A6.1, A6.2, and H6.1 were pro-
duced in INTEGRA Celline CL1000 flasks (Integra Biosciences, Ijamsville, MD)
as previously described (33). Anti-MNV MAb A6.2 has been previously reported
(24, 57). We used the same methods to isolate additional neutralizing MAbs A6.1
and H6.1 specific for the MNV capsid (data not shown). The titer of anti-MNV
antibody in serum was determined by using enzyme-linked immunosorbent assay
(ELISA) (23).
Mice and infections. All mice were bred and housed at Washington University
School of Medicine in accordance with all federal and university policies. Wild-
type C57BL/6/J (B6; Jackson Laboratory, catalog no. 000664), B6RAG1/
(RAG1/, Jackson Laboratory, catalog no. 002216), and MT (25) mice back-
crossed onto a C57BL/6 background (MT; Jackson Laboratory, catalog no.
002288) mice were purchased from the Jackson Laboratory (Bar Harbor, ME).
HELMET mice, which express an IgM/IgD transgenic B-cell receptor specific for
hen egg lysozyme, were generated and bred as previously described (34). Wild-
type mice were tested by ELISA for the presence of MNV antibody prior to
experiments (23). All mice used in these studies were seronegative. RAG1/,
and all splenocyte donor mice were infected with 3  106 PFU of virus p.o. in 25
l of Dulbecco modified Eagle medium supplemented with 10% fecal bovine
serum (HyClone, Logan, UT). All other mice were infected with 3  107 PFU
p.o. In RAG1/ mice, two segments of the small intestine were harvested: a
1-in. section of the small intestine immediately distal to the pylorus of the
stomach (designated the duodenum/jejunum) and a 1-in. section of the small
intestine immediately proximal to the cecum (designated the distal ileum). In all
other mice the distal ileum and three mesenteric lymph nodes (MLN) were
harvested. The duodenum/jejunum was not harvested from wild-type mice since
virus titers could not be detected at this site.
Adoptive and passive transfer studies. Spleens were harvested from mice, and
single-cell suspensions were generated. Cells were counted and diluted in RPMI
1640 media (Sigma, St. Louis, MO) supplemented with 10% fetal calf serum
(SH30071.03; HyClone), 100 U of penicillin/ml, 100 g of streptomycin/ml, 10
mM HEPES, 1 mM sodium pyruvate, 2-mercaptoethanol, and 2 mM L-glutamine
(cRPMI). A total of 107 cells were injected into persistently infected RAG1/
mice by intraperitoneal (i.p.) injection in 0.5 ml of cRPMI. Immune and control
antiserum was obtained from either immunized or control mice, filtered (0.2-m
pore size), heat fixed for 30 min at 55°C, and then stored for use. Sera and MAbs
were passively transferred into recipient mice i.p.
Statistical methods. All data were analyzed by using Prism software (Graph-
Pad Software, San Diego, CA). Virus titers were analyzed with the nonparamet-
ric Mann-Whitney test. All differences not specifically stated to be significant
were insignificant (P  0.05).
RESULTS
B cells are required to control early mucosal MNV replica-
tion and long-term clearance in MLN but not intestine. We
have previously demonstrated that RAG1/ mice, which are
deficient in both T cells and B cells, develop a chronic persis-
tent MNV infection (23), whereas wild-type mice efficiently
clear infection. This indicates that adaptive immunity is impor-
tant for MNV clearance. To evaluate the role of B cells in the
control of primary MNV infection, we compared MNV titers
in MT (B-cell-deficient) mice and wild-type B6 mice in the
distal ileum and the MLN after p.o. infection. Previous work
has shown that MNV replicates in both the distal ileum and the
MLN (17, 18, 35, 48). At 3 and 5 days postinfection, MT mice
had significantly higher virus titers compared than did wild-
type controls in the distal ileum (P  0.002 and P  0.014, Fig.
1A) and also in the MLN (P  0.009 and P  0.0004, Fig. 1B).
The majority of both wild-type B6 and MT mice cleared ileal
infection by day 7 postinfection, with only 2 of 10 MT mice
having any measurable ileal titer at this time point (Fig. 1A). In
the MLN, wild-type mice cleared infection by day 7, whereas in
MT mice titers on average decreased 100-fold from their
FIG. 1. B cells limit MNV replication and are required for MNV
clearance in the distal ileum and MLN. Virus titers in the distal ilea
(A) and MLN (B) of B6 and MT mice. These data are pooled from
at least two independent experiments with five mice per group in each
experiment, and each symbol indicates a sample from an individual
mouse. *, P  0.05. LD, limit of detection.
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peak at 5 days postinfection. However, MLN titers in MT
mice remained detectable at days 7, 10, and 21 postinfection.
The difference between wild-type B6 and MT mice was sta-
tistically significant at these time points (day 7, P  0.0004; day
10, P  0.045; and day 21, P  0.045 [Fig. 1B]). These data
showed that B cells were important in the control of MNV
infection at days 3 and 5 in both the distal ileum and the MLN.
However, while B cells were dispensable for clearance of MNV
in the distal ileum, they were required for the clearance of
infection from MLN.
B cells are required to efficiently clear ileal MNV infection
after adoptive transfer of immune cells. The experimental
results depicted in Fig. 1 showed a critical role for B cells in the
control of ileal replication early after infection and for elimi-
nation of MNV infection from the mesenteric lymphatics. B
cells can function to control viral infection via either antibody
production or via antibody-independent effects such as priming
an effective T-cell response (34). To address the mechanism of
B-cell action, we turned to passive and adoptive-transfer
experiments.
We first determined whether mice that have made a sero-
logic response to MNV contain immune cells capable of clear-
ing ileal MNV infection. We mock and MNV infected wild-
type mice, and at 35 to 42 days postinfection we harvested sera
and splenocytes from these mice. Compared to mock-infected
mice, MNV-infected B6 mice developed a substantial IgG re-
sponse to MNV virions by 35 to 42 days postinfection (P 
0.0001, Fig. 2A). This is consistent with our previous reports
and the work of others (17, 18, 23, 40, 48, 53).
Since MNV-infected RAG1/ mice develop a persistent
ileal infection, these mice provide an excellent model for de-
fining immune mechanisms of clearance of mucosal MNV in-
fection. We chose to further explore the clearance of MNV
infection because we were interested in determining the im-
mune factors that are required for the abrogation of an al-
ready-established viral infection. Persistently infected
RAG1/ mice provide a broad time frame in which an estab-
lished infection is not cleared and, in the absence of an adap-
tive immune response, we could test individual aspects of
adaptive immunity and determine their role in the clearance of
MNV infection. Further, the lack of an adaptive immune re-
sponse allows establishment of MNV infection in the duode-
num/jejunum, a site where MNV replication cannot be de-
tected in wild-type B6 mice (data not shown). This shows that
either T or B cells or both lymphocyte subsets are important
for resistance to MNV infection in this tissue. The duodenum/
jejunum provides a second tissue for analysis of the role of B
cells and antibody in control of MNV infection.
Compared to nonimmune splenocytes, splenocytes har-
vested from immune wild-type mice were able to effectively
clear MNV infection from the distal ileum 6 days after adop-
tive transfer into persistently infected RAG1/ mice (Fig. 2B,
P  0.0001). This system allowed us to (i) test whether B cells
were necessary for the clearance of persistent MNV infection
and (ii) test whether the capacity of B cells to make antiviral
antibodies was important.
To determine whether B cells were necessary for the clear-
ance of MNV, splenocytes were obtained from MT mice at 35
to 42 days postinfection. At this time there was no detectable
virus titer in the spleens of these mice (data not shown). These
MT splenocytes were adoptively transferred into persistently
infected RAG1/ recipients. In contrast to immune spleno-
cytes from wild-type mice, the splenocytes from MT mice
were unable to clear MNV infection in either the duodenum/
jejunum (Fig. 3A) or the distal ileum (Fig. 3B) of RAG1/
recipients at 6 days after transfer.
We wanted to determine whether, in the absence of B cells
and antibody, the cells that remained in the spleen (including
T cells) were capable of clearing MNV infection or whether B
cells were essential for clearance at later times after the trans-
fer of immune splenocytes into RAG1/ recipients. We
therefore measured virus titers at 14 and 21 days after transfer
of MT cells into recipient mice. At 14 and 21 days after
transfer, there was a significant reduction in the virus titers in
the duodenum and jejunum (P  0.005 and P  0.0001, re-
spectively; Fig. 3A), as well as in the distal ileum (P  0.0002
and P  0.004, respectively; Fig. 3B). This showed that im-
mune cells other than B cells can decrease mucosal infection
with MNV. However, MNV was not cleared completely from
mucosal sites in all RAG1/ recipients even 21 days after
transfer. We concluded two things from these experiments.
First, B cells or antibody were critical for efficient clearance of
MNV infection from mucosal sites. Second, in the absence of
B cells, the remaining immune cells, presumably T cells, were
able to reduce virus titers but not completely clear infection.
FIG. 2. Antibody responses and capacity of adoptively transferred
immune splenocytes to clear enteric MNV infection. (A) Levels of
serum anti-MNV IgG antibody determined by ELISA (1:100 serum
dilution) in mock- and MNV-immunized wild-type B6 mice 35 to 42
days postinfection. (B) Virus titers in the distal ileum of persistently
infected RAG1/ mice 6 days after transfer of medium alone, non-
immune splenocytes, or immune splenocytes. These data are pooled
from three independent experiments with three to five mice per group
in each experiment. **, P  0.0001; *, P  0.05. LD, limit of detection.
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The requirement for B cells is antibody dependent: antiviral
antibody is involved in the clearance of mucosal MNV infec-
tion. We next wanted to determine whether the requirement
for B cells was due to the production of antiviral antibody. We
therefore studied HELMET mice, which are HEL-specific
IgM/IgD B-cell receptor mice bearing the IgMa allotype bred
onto the B cell/ background (34). These mice have B cells
that produce only HEL-specific antibody and do not mount an
antiviral antibody response (34). However, these B cells can
support normal levels of T-cell responses (34). We obtained
splenocytes from MNV-immunized HELMET mice at 35 to 42
days postinfection, at which time no virus titers could be de-
tected in the spleen (data not shown). Splenocytes from
HELMET mice were adoptively transferred into persistently
infected RAG1/ mice to determine whether B cells have a
role in MNV clearance that is independent of antibody pro-
duction. This was a particularly relevant question since T cells
had some capacity to control mucosal MNV infection (Fig. 3
and data not shown) and B cells can support the development
of antiviral T cells (34). We measured virus titers in the intes-
tine of recipient RAG1/ mice 6 days after adoptive transfer.
No significant difference was noted between control mice that
did not receive any donor splenocytes and mice that received
splenocytes from HELMET donors in either the duodenum/
jejunum or the distal ileum (Fig. 3C and D). In addition, no
significant difference was noted between recipients of spleno-
cytes from MT donors and recipients of splenocytes from
HELMET donors (compare Fig. 3A and B with Fig. 3C and
D). Thus, we concluded that the requirement for B cells in the
efficient control of MNV infection was due to the production
of virus-specific antibody.
MNV specific polyclonal sera and IgG are sufficient to limit
MNV replication in the intestine and spleen. Since the transfer
of immune HELMET splenocytes linked the importance of B
cells in the efficient clearance of MNV infection to a role for
MNV-specific antibody, we directly tested the ability of pas-
sively transferred anti-MNV antibody to limit viral replication.
To obtain MNV specific polyclonal antibody, we mock im-
munized or MNV immunized wild-type mice and 35 to 42 days
postinfection obtained nonimmune and immune serum. We
transferred 500 l of serum via i.p. injection into persistently
infected RAG1/ mice and measured virus titers in the distal
ileum and spleen 6 days after transfer. In the distal ileum,
transfer of immune serum led to a modest, but significant
decrease in the levels of MNV titer compared to nonimmune
serum transfers (P  0.013, Fig. 4A). Similar results were
obtained in the duodenum/jejunum (data not shown). In the
spleen, the transfer of immune serum had a much more sig-
nificant effect of reducing the levels of MNV titer to below the
levels of detection in half of the mice examined (P  0.0001).
This demonstrated that MNV immune polyclonal serum is
sufficient to reduce MNV titers in the intestine and spleen.
FIG. 3. B cells and antiviral antibody production are essential for efficient clearance of MNV infection from intestine of persistently infected
RAG1/ mice. Virus titers in the duodena/jejuna (A and C) and distal ilea (B and D) of persistently infected RAG1/ recipients after adoptive
transfer of medium (mock), immune wild type, MT splenocytes (A and B) or HELMET splenocytes (C and D). These data are pooled from three
independent experiments with three to five mice per group in each experiment. **, P  0.0001; *, P  0.05. LD, limit of detection.
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Even though IgA is classically thought of as the main anti-
body isotype present at the mucosal surface (reviewed in ref-
erence 36), there are reports of IgG antibody controlling mu-
cosal viral infection (26, 38, 55). We therefore wanted to
determine whether IgG antibodies against MNV capsid alone
could reduce MNV titers. We obtained three anti-MNV capsid
MAbs—A6.1, A6.2, and H6.1, all of the IgG2a isotype—that
had previously been shown to neutralize MNV in vitro (24, 57;
unpublished data). We administered 500 g of each antibody
via i.p. injection into persistently infected RAG1/ mice. In
the distal ileum, each of the MAbs was able to significantly
reduce the levels of MNV titers compared to mice injected
with the 9BG5 control antibody (P  0.0002) in each case (Fig.
4C). Furthermore, in the spleen, all three MAbs (A6.1, A6.2,
and H6.1) were also able to significantly reduce the levels of
MNV titers (P  0.0002, P  0.0004, and P  0.0207, respec-
tively; Fig. 4D). This demonstrated that MAbs of the IgG
isotype directed against MNV capsid were able to control
MNV infection in the distal ileum and spleen.
DISCUSSION
Noroviruses are the cause of more than 95% of epidemic
nonbacterial gastroenteritis worldwide and are also a common
cause of intestinal infectious disease in the community (8, 11,
49, 56). The immune mechanisms involved in clearance of
norovirus infection are not completely understood. Human
volunteer studies show short-lived immunity to homologous
viral challenge, but the role of antibody in this protection is not
known (9, 39, 59). The availability of a culturable, enteric
MNV allows the use of immunodeficient mice to identify the
immune mechanisms required to control and eliminate muco-
sal, lymphatic, and systemic norovirus infection (23, 24, 35, 54,
57). It is important to note that the relationship between the
pathogenesis of MNV infection and human norovirus infection
is not clear (58). However, MNV is an efficient enteric virus,
infecting a broad array of mice in research colonies (18, 48, 53)
and sharing fundamental mechanisms of replication (43) and
structure (24) with human noroviruses. We therefore believe
that mechanistic studies of MNV immunity in well-defined
mouse systems may provide valuable insights into conserved
aspects of norovirus immunity.
In the present study we focus on the role of B cells and
antibody, deriving four primary conclusions. First, B cells are
important for control of ileal and lymphatic MNV infection
early (3 to 5 days after) after oral infection. Second, the role of
B cells later in infection is tissue specific; the ileum can be
cleared of infection without B cells, but B cells are important
for the clearance of infection from the enteric lymphatic sys-
tem even 3 weeks after infection. Third, the role of B cells is in
large part due to the production of antiviral antibody. Fourth,
IgG antibodies can play a role in clearance of mucosal MNV
infection. Together, these findings provide the first compre-
hensive view of the role of the serologic response in control of
mucosal and lymphatic norovirus infection.
Role of B cells early after oral infection. B-cell-deficient
MT mice were defective in the control of MNV replication in
the distal ileum and MLN at 3 and 5 days postinfection. At
FIG. 4. Immune serum and neutralizing IgG MAbs reduce MNV infection from intestines and spleens of RAG1/ mice. Virus titers in distal
ilea (A and C) and spleens (B and D) of persistently infected RAG1/ recipients 6 days after passive transfer of either immune serum (A and
B) or neutralizing MAbs specific for capsid protein (C and D). These data are pooled from three independent experiments with three mice per
group in each experiment. **, P  0.0001; *, P  0.05. LD, limit of detection.
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such early times after infection no virus-specific IgG can be
detected. However, the strain of MT mice used in these
experiments (MT mice) can produce small amounts of virus-
specific IgA (31). Thus, increased titers of MNV early after
infection might be due to a relative defect in IgA production by
MT mice compared to wild-type B6 mice. However, 3 days is
a very short time to mount a physiologically significant virus-
specific antibody response. We therefore believe it more likely
that the increased replication of MNV in MT mice compared
to wild-type mice early after infection may reflect a role for
natural antibody in MNV infection. Validating this hypothesis
will require further experiments. Natural antibodies produced
by B1 B cells can play a role in the control of some mucosal
pathogens, including viruses. However, other explanations are
possible, and these are the subject of ongoing investigations.
Tissue-specific role of B cells during MNV infection. Al-
though the distal ileum of B-cell-deficient mice was cleared of
MNV infection by 7 days after infection, the MLN was not.
Thus, the clearance of MNV infection from intestinal lym-
phatic tissue is more dependent on B cells than the clearance
of ileal infection. The reason for this is not clear. It may be that
the cellular tropism of MNV is different in these different sites
and that B cells are more important for elimination of MNV
from some tissues than others. Of note, however, passive trans-
fer of polyclonal immune serum and MAbs into persistently
infected RAG1/ mice was capable of limiting ileal MNV
replication. Thus, IgG does have access to relevant sites of
MNV replication in the ileum and can be effective in this
tissue. An alternative explanation is that other effector mech-
anisms, such as T cells, are more effective in the ileum than in
the lymphatic system. Arguing against this, however, is the fact
that adoptively transferred immune cells lacking B cells were
not completely able to clear MNV from the ileum even late
after infection. However, since RAG1/ mice do not have
normal MLN, these adoptive- and passive-transfer experi-
ments into persistently infected RAG1/ mice shed no light
on the role of IgG per se in lymphatic infection.
Role of antiviral IgG in B-cell-dependent control of mucosal
MNV infection. The role of B cells in the control of MNV
infection appears to be primarily due to the production of
antiviral antibody. The data supporting this conclusion include
the lack of effectiveness of immune cells from both B-cell-
deficient MT mice and HELMET mice in controlling muco-
sal MNV infection in adoptive-transfer experiments. This is
consistent with a role for antiviral antibody since HELMET
mice have B cells and produce antibody to HEL but cannot
mount an antiviral antibody response (33, 34). Furthermore,
passive transfer of polyclonal antiserum decreased mucosal
MNV infection. This latter result was obtained via passive
transfer of 0.5 ml of serum, which represents less than the
volume of serum in a naturally immune mouse. Thus, by def-
inition, the effect of immune serum was observed at physiolog-
ically relevant antibody concentrations. We further found that
IgG MAbs can significantly decrease MNV infection at muco-
sal sites. Together, these data argue that systemic IgG can have
a significant effect on mucosal norovirus infection. Although
our experiments with IgG MAbs provide proof of concept that
IgG can have significant mucosal effects, the amount of specific
IgG isotypes, or the specific epitope targets of such IgGs, that
would have to be elicited by a vaccine to alter mucosal infec-
tion remains an open question. Our data show that the capsid
protein is a target for neutralizing IgG. Additional viral pro-
teins may be targets of protective antibodies or may induce
protective immunity by other mechanisms.
Comparison of our results to those obtained for other en-
teric viruses. The role of B cells and antibody has been exten-
sively documented in both reovirus and rotavirus infection.
Using B-cell-deficient mice, it has been determined that B cells
are required for long-term robust protection against rotavi-
ruses (12). In mice, both IgG and IgA are important in control
of rotavirus (60). However, while intestinal IgA is an efficient
mechanism of rotavirus clearance, it is clear that virus specific
IgG or IgM, if present in the intestine or present in large
quantities in serum, can also mediate protection in the intes-
tine (26, 38, 55). In both rotavirus and reovirus, virus specific
antibody can control systemic infection and spread (6, 42, 50–
52) as well as primary intestinal infection (3). In this aspect,
murine norovirus infections is similar to both rotavirus and
reovirus infection, indicating a conserved role for systemic
antibody at mucosal sites. Targeting robust systemic IgG re-
sponses may therefore be a valid goal for establishing effective
mucosal protection against norovirus and other enteric virus
infections.
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